Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

(2015) Johnathan M. Lancaster et al.   GYNECOLOGIC ONCOLOGY

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

(2015) Fergus J. Couch et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

The changing landscape of genetic testing for hereditary breast and ovarian cancer

(2014) Cecelia A. Bellcross   CURRENT PROBLEMS IN CANCER

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

(2013) Nasim Mavaddat et al.   JNCI-Journal of the National Cancer Institute

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

(2012) Kathryn Alsop et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA in breast cancer: ESMO Clinical Practice Guidelines

(2011) J. Balmana et al.   ANNALS OF ONCOLOGY

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

(2011) Anne-Renee Hartman et al.   CANCER

ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

(2011) Amanda B. Spurdle et al.   HUMAN MUTATION

Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family

(2010) Orland Diez et al.   BREAST CANCER RESEARCH AND TREATMENT

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation inBRCA1orBRCA2

(2010) Kathleen E. Malone et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET